Advertisement

Advertisement

CGEM Stock Latest News

Cullinan Maintained at Buy as Advancing Autoimmune and Oncology Pipeline Supports Unchanged $36 Price Target

RatingsCullinan Maintained at Buy as Advancing Autoimmune and Oncology Pipeline Supports Unchanged $36 Price Target

Cullinan Therapeutics reports Q2 EPS (81c), consensus (85c)

PremiumThe Fly

Cullinan Therapeutics reports Q2 EPS (81c), consensus (85c)

11h ago

Cullinan Therapeutics Launches Early Trial of Velinotamig in Hard‑to‑Treat Blood Disorders

PremiumCompany Announcements

Cullinan Therapeutics Launches Early Trial of Velinotamig in Hard‑to‑Treat Blood Disorders

6d ago

Cullinan Therapeutics price target raised to $39 from $38 at BTIG

PremiumThe Fly

Cullinan Therapeutics price target raised to $39 from $38 at BTIG

8d ago

Analyst Reiterates Buy on CGEM as CLN-049 Advances Toward Registrational Phase 2; Price Target Raised to $39 on Improved Risk-Reward

PremiumRatings

Analyst Reiterates Buy on CGEM as CLN-049 Advances Toward Registrational Phase 2; Price Target Raised to $39 on Improved Risk-Reward

8d ago

Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA

PremiumThe FlyCullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA

9d ago

Cullinan Therapeutics management to meet with BTIG

The Fly

Cullinan Therapeutics management to meet with BTIG

23d ago

Cullinan Therapeutics Shareholders Back Directors and Governance Measures

Company Announcements

Cullinan Therapeutics Shareholders Back Directors and Governance Measures

2M ago

Cullinan Therapeutics price target raised to $46 from $33 at Clear Street

PremiumThe Fly

Cullinan Therapeutics price target raised to $46 from $33 at Clear Street

2M ago

Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data

PremiumCompany Announcements

Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data

2M ago

Cullinan Therapeutics reports CLN-978, velinotamig data

PremiumThe Fly

Cullinan Therapeutics reports CLN-978, velinotamig data

2M ago

Buy Rating on Cullinan Reinforced by Encouraging Early CLN-978 Autoimmune Data and High Upside Potential

PremiumRatings

Buy Rating on Cullinan Reinforced by Encouraging Early CLN-978 Autoimmune Data and High Upside Potential

2M ago

Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data

PremiumCompany AnnouncementsCullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data

2M ago

Cullinan Therapeutics Reiterated as Buy on Promising CLN-978 Data; $30 Price Target Maintained

Ratings

Cullinan Therapeutics Reiterated as Buy on Promising CLN-978 Data; $30 Price Target Maintained

2M ago

Cullinan Therapeutics presents clinical data for CLN-978

The Fly

Cullinan Therapeutics presents clinical data for CLN-978

2M ago

Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors

PremiumCompany Announcements

Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors

2M ago

Cullinan to host Immunology Day event, announce data for CLN-978, Velinotamig

PremiumThe Fly

Cullinan to host Immunology Day event, announce data for CLN-978, Velinotamig

2M ago

Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street

PremiumThe Fly

Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street

3M ago

Cullinan Therapeutics receives orphan drug designation for CLN-049

PremiumThe Fly

Cullinan Therapeutics receives orphan drug designation for CLN-049

3M ago

Cullinan Management Shares Promising Early CLN-978 Autoimmune Data

PremiumCompany AnnouncementsCullinan Management Shares Promising Early CLN-978 Autoimmune Data

3M ago

Cullinan Therapeutics price target raised to $37 from $36 at Wedbush

The Fly

Cullinan Therapeutics price target raised to $37 from $36 at Wedbush

3M ago

Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c)

The Fly

Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c)

3M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >